American Regent, Inc. is recalling three lots of its injectable epinephrine after finding that some vials leaked, cracked, or carried visible particulate matter, a defect the company says can be lethal if the drug is injected anyway. The recall covers 30 mg/30 mL multi-dose vials of Epinephrine Injection, USP, a concentration used in hospitals and clinics rather than the single-dose auto-injectors most consumers know as EpiPens. Announced September 3, 2026, the recall reaches back to product already sitting in pharmacies and hospital stock rooms nationwide.
What makes this recall unusual is not the packaging defect itself but the specific mechanism the company laid out for how it could hurt someone. A cracked vial is a shipping problem; particulate matter injected into a vein is a circulatory one, and the company’s own filing spells out exactly what that means for a patient’s bloodstream.
Cracked Vials Let Sterility and Solid Particles In
The defect traces back to customer complaints about vials that were leaking or physically cracked, which broke the seal meant to keep the drug sterile. Once that seal fails, American Regent’s investigation found, the vial can no longer guarantee the liquid inside stayed free of contamination or of solid material shed by the packaging itself.
Testing on the affected lots turned up five distinct materials suspended in the liquid: nylon, cellulosic fiber, acrylic, polyethylene and glass. None of those belong in an injectable drug at any concentration, and their presence is what triggered the recall rather than a potency or dosing problem with the epinephrine itself.
Multi-dose vials carry an added complication that single-use vials do not: a rubber stopper gets punctured repeatedly as staff draw successive doses, and each puncture is a fresh opportunity for a compromised seal to shed material into the remaining liquid. A vial used early in its life might dispense clean doses before a growing crack finally lets contamination reach the drug toward the bottom of the supply.
Particulate Matter Can Choke Off Blood Flow to Organs
American Regent’s recall notice describes a specific chain of harm: particulate matter injected intravenously can cause blockage and clotting inside blood vessels, cutting off blood flow to vital organs. The same particles can travel to the lungs and trigger a pulmonary embolism, a blood clot serious enough to be life-threatening on its own.
Beyond the clotting risk, the company warns that trapped particles can cause permanent organ damage or death independent of any clot forming at all, simply by lodging in small vessels that organs depend on for oxygen. That combination of risks, laid out in the plain language of a federal recall filing, is why the product’s use is being stopped even though epinephrine itself is not the problem.
Epinephrine injection is typically given in an emergency, often to a patient already in distress from anaphylaxis, cardiac arrest or severe asthma, which leaves clinicians little time to visually inspect a vial before drawing a dose. That urgency is exactly why a defect capable of introducing solid particulates matters more for this drug than it might for a medication given on a slower, more deliberate schedule.
Three Lots Tie the Recall to a Specific Manufacturing Window
The recall is limited to three lot numbers — 25128L1C0, 25280L1C0 and 26108L1C0 — all sold under the same National Drug Code, 0517-3030-01. American Regent’s own tracking shows those lots reached distributors and pharmacies at different points between September 2025 and July 2026, meaning affected vials could plausibly still be sitting unused on a shelf more than a year after the earliest batch shipped.
Limiting the recall to named lots rather than the entire product line lets pharmacies and hospitals keep dispensing unaffected epinephrine vials rather than losing the drug from supply entirely, which matters for a medication used in emergencies where a substitute is not always on hand. Epinephrine shortages have hit the United States before, and a blanket recall of every lot on the market would have created exactly the kind of gap hospitals try hardest to avoid for a drug used to treat anaphylaxis and cardiac arrest.
No Injuries Reported Yet, but the Company Is Not Waiting for One
American Regent’s recall notice, posted through the FDA’s public alert system, states the company has not received any reports of adverse events tied to the affected lots. That absence of harm so far is what makes this a voluntary, precautionary action rather than a response to a documented injury, and it is also why the company moved on visible defects and lab-confirmed particulates rather than waiting for a patient outcome to force the issue.
Pharmacies and hospitals that received the three lots are being told to quarantine remaining stock and to stop dispensing units from the affected batches immediately. Patients or providers who already have vials from those lots are directed to return them through their normal supplier rather than to a pharmacy counter, since the multi-dose vials in question are typically stocked by facilities rather than sold directly to individual patients.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
